External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO BC 2024
Roche and Genentech at

ESMO BC 2024

May 15 - May 17
Berlin, Germany / Virtual (Hybrid)
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
May 16 / Roche and Genentech
Atezolimab (A) + pertuzumab + trastuzumab (PH)▼ + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial
IMpassion050 (NCT03726879) was a phase III, double-blind, randomised, international, multicentre, placebo-controlled study, which evaluated efficacy and safety of neoadjuvant atezolizumab or placebo, each combined with pertuzumab, trastuzumab▼ and chemotherapy. This poster reports long-term efficacy results (event-free survival and disease-free survival) and safety results from the adjuvant phase.
Oncology Breast Cancer ESMO-BREAST-CANCER-2024

Sign up or login to unlock the full suite of MEDICALLY features
May 16 / Roche and Genentech
Fixed-dose combination of pertuzumab and trastuzumab▼ for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre Phase III (neo)adjuvant FeDeriCa study
FeDeriCa (NCT03493854) is a phase III (neo)adjuvant study of the fixed-dose combination of pertuzumab and trastuzumab▼ for subcutaneous injection in combination with chemotherapy in patients with centrally confirmed HER2-positive invasive breast cancer (tumour >2 cm, or node-positive disease; Stage II–IIIC). This poster reports long-term efficacy and safety results from the final analysis.
Oncology Breast Cancer ESMO-BREAST-CANCER-2024

Sign up or login to unlock the full suite of MEDICALLY features
May 15 / Roche and Genentech
Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
MORPHEUS-panBC (NCT03424005) is a Phase Ib/II, open-label, multicentre, randomised umbrella study of multiple treatment combinations in locally advanced/metastatic breast cancer. In this presentation, an 18-week interim analysis of the atezolizumab + sacituzumab govitecan arm in patients with first-line, PD-L1-positive, metastatic triple-negative breast cancer is presented.
Oncology Breast Cancer ESMO-BREAST-CANCER-2024
03:09 PM
Duration 70mins Berlin Hall
Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
Schmid P, Loi S, De la Cruz L, Yerushalmi R, Im SA, Sonnenblick A, Martinez M, Moreno I, Kennedy L, Griffiths K, Schwab R, Young F, Liao L, Dupree K, Kim SB
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:57 PM
Duration 70mins Berlin Hall
IMpassion132 double-blind randomised phase 3 trial of chemotherapy ± atezolizumab for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer
R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kummel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, Z.K. Machackova, J. Mouta, R.J. Deurloo, X. Gan, M. Fan, A. Swat and J. Cortés
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 60mins Berlin, Germany
Atezolimab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial
Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, SL Huggins-Puhalla, Pedrini J, Zhukova L, Curran M, Eiger D, Craine V, Lambertini C, Restuccia E, Zhang H
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Berlin, Germany
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre Phase III (neo)adjuvant FeDeriCa study
Jackisch C, Im S-A, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga J-Y, Jung KH, Schem C, Heeson S, Crane V, Wang B, Restuccia E, Tan A
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.